Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Mar;10(3):226-228.
doi: 10.1016/S2213-2600(22)00050-9. Epub 2022 Feb 9.

Convalescent plasma in outpatients with COVID-19

Daniele Focosi  1 , Arturo Casadevall  2
Affiliations
Comment

Convalescent plasma in outpatients with COVID-19

Daniele Focosi et al. Lancet Respir Med. 2022 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

DF was an investigator in the TSUNAMI randomised controlled trial of COVID-19 convalescent plasma. AC reports being part of the scientific advisory board of SabTherapeutics, has received personal fees from Ortho Diagnostics, outside of the submitted work, and is an investigator in the CSSC-004 randomised controlled trial.

Comment on

  • High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.
    Alemany A, Millat-Martinez P, Corbacho-Monné M, Malchair P, Ouchi D, Ruiz-Comellas A, Ramírez-Morros A, Rodríguez Codina J, Amado Simon R, Videla S, Costes G, Capdevila-Jáuregui M, Torrano-Soler P, San José A, Bonet Papell G, Puig J, Otero A, Ruibal Suarez JC, Zarauza Pellejero A, Llopis Roca F, Rodriguez Cortez O, Garcia Garcia V, Vidal-Alaball J, Millan A, Contreras E, Grifols JR, Ancochea À, Galvan-Femenia I, Piccolo Ferreira F, Bonet M, Cantoni J, Prat N, Ara J, Forcada Arcarons A, Farré M, Pradenas E, Blanco J, Àngel Rodriguez-Arias M, Fernández Rivas G, Marks M, Bassat Q, Blanco I, Baro B, Clotet B, Mitjà O; CONV-ERT Group. Alemany A, et al. Lancet Respir Med. 2022 Mar;10(3):278-288. doi: 10.1016/S2213-2600(21)00545-2. Epub 2022 Feb 9. Lancet Respir Med. 2022. PMID: 35150610 Free PMC article. Clinical Trial.

References

    1. Alemany A, Millat-Martinez P, Corbacho-Monné M, et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respir Med. 2022 doi: 10.1016/S2213-2600(22)00050-9. published online Feb 9 . - DOI - PMC - PubMed
    1. Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med. 2021;384:610–618. - PMC - PubMed
    1. Sullivan DJ, Gebo KA, Shoham S, et al. Randomized controlled trial of early outpatient COVID-19 treatment with high-titer convalescent plasma. medRxiv. 2021 doi: 10.1101/2021.12.10.21267485. published online Dec 21. (preprint). - DOI
    1. Millat-Martinez P, Gharbharan A, Alemany A, et al. Convalescent plasma for outpatients with early COVID-19. medRxiv. 2021 doi: 10.1101/2021.11.30.21266810. published online Dec 2. (preprint). - DOI
    1. Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with COVID-19. N Engl J Med. 2021;385:1951–1960. - PMC - PubMed